Incretins

DBCAT001316Pharmacologic class

Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially. A DrugBank category of 9 drugs. 8 of them are approved.

Part of: Blood Glucose Lowering Agents
Also known as: Effect, Incretin · Effects, Incretin · Glucose Dependent Insulin Releasing Hormone · Glucose-Dependent Insulin-Releasing Hormone · Hormone, Glucose-Dependent Insulin-Releasing
Drugs: Albiglutide
Alogliptin
Exenatide
Gastric inhibitory polypeptide
Linagliptin
Liraglutide
Saxagliptin
Sitagliptin
Tirzepatide

What you can answer from here — as of June 06, 2018

9DrugsEach linked to its full drug card

Listed above

4Drug targetsEvery drug–target pair in the class, with bond type

2,548Marketed productsAcross the regions we cover, with dosage forms and routes

3Routes of administrationHow the drugs in this class are given

Which targets do Incretins share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account